Evidence map›Paper›PMID 24909953›Full record

ArticleJournal of biomedical materials research. Part B, Applied biomaterials2015

Bone tissue engineering with a collagen-hydroxyapatite scaffold and culture expanded bone marrow stromal cells.

Max M Villa, Liping Wang, Jianping Huang, David W Rowe, Mei Wei

Abstract read
In one paragraph

Article in Journal of biomedical materials research. Part B, Applied biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Mussel-inspired biomaterials: From chemistry to clinic.Bioengineering & translational medicine · 2022
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Max M VillaDepartment of Materials Science and Engineering, University of Connecticut, Storrs, Connecticut, 06269-3136.
Liping Wang
Jianping Huang
David W Rowe
Mei Wei

Funding

Targeted Correction of Dominant Mutations of Type I Collagen Causing Severe OIR01AR064381 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROWE, DAVID W. · 2013 to 2017
$1.7M
4-D Imaging Cell/Scaffold Interplays During In Vivo Bone Repair ProcessR21AR059962 · NIAMS · UNIVERSITY OF CONNECTICUT STORRS · PI ROWE, DAVID W., WEI, MEI · 2011 to 2012
$382k
NIAMS NIH HHS 1R21AR059962-01A1NIAMS NIH HHS 3 R01 AR064381-01S1NIAMS NIH HHS R01 AR064381NIAMS NIH HHS R21 AR059962
6 · The paper itself

Abstract

Osteoprogenitor cells combined with supportive biomaterials represent a promising approach to advance the standard of care for bone grafting procedures. However, this approach faces challenges, including inconsistent bone formation, cell survival in the implant, and appropriate biomaterial degradation. We have developed a collagen-hydroxyapatite (HA) scaffold that supports consistent osteogenesis by donor-derived osteoprogenitors, and is more easily degraded than a pure ceramic scaffold. Herein, the material properties are characterized as well as cell attachment, viability, and progenitor distribution in vitro. Furthermore, we examined the biological performance in vivo in a critical-size mouse calvarial defect. To aid in the evaluation of the in-house collagen-HA scaffold, the in vivo performance was compared with a commercial collagen-HA scaffold (Healos(®) , Depuy). The in-house collagen-HA scaffold supported consistent bone formation by predominantly donor-derived osteoblasts, nearly completely filling a 3.5 mm calvarial defect with bone in all samples (n = 5) after 3 weeks of implantation. In terms of bone formation and donor cell retention at 3 weeks postimplantation, no statistical difference was found between the in-house and commercial scaffold following quantitative histomorphometry. The collagen-HA scaffold presented here is an open and well-defined platform that supports robust bone formation and should facilitate the further development of collagen-hydroxyapatite biomaterials for bone tissue engineering.

Indexed as

Bone SubstitutesCollagenDurapatiteOsteogenesisTissue EngineeringAnimalsBone Marrow CellsMiceMice, Inbred NODOsteoblastsSkullStromal CellsTissue ScaffoldsBone SubstitutesCollagenDurapatitebonebone marrowcollagenstem cellstissue engineering

Identifiers

PMID24909953
PMCPMC4380129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.